Co-treatment of tuberculosis and HIV: Pharmacologic considerations

Ethel D. Weld, Alice K. Pau, Gary Maartens, Kelly E. Dooley

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Having HIV and TB worsens the impact of both. The treatment of HIV-TB coinfection is beset by challenges, including drug-drug-interactions, coincident toxicities, and the occurrence of the immune reconstitution inflammatory syndrome. These challenges can be overcome with careful attention to evidence-guided practice and clinical pharmacological aspects of co-treatment. There is a clear mortality benefit to treating both infections; the relative timing of initiation of both treatments will be discussed. This chapter will address pharmacologic considerations in the co-treatment of HIV-related latent or active TB of all sensitivity patterns (drug sensitive and multidrug resistant (MDR). The discussion will identify existing gaps in the evidence and include current recommendations for HIV-TB treatment in special populations, including pregnant and lactating women and children.

Original languageEnglish (US)
Title of host publicationHIV and Tuberculosis
Subtitle of host publicationA Formidable Alliance
PublisherSpringer International Publishing
Pages239-267
Number of pages29
ISBN (Electronic)9783030291082
ISBN (Print)9783030291075
DOIs
StatePublished - Jan 1 2019

Keywords

  • Co-management
  • Drug-drug-interactions
  • HIV
  • Pharmacology
  • Tuberculosis

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'Co-treatment of tuberculosis and HIV: Pharmacologic considerations'. Together they form a unique fingerprint.

Cite this